Burden of New-Onset Atrial Fibrillation in Adults With Acute Myocardial Infarction A Multicenter Prospective Study Using Continuous Electronic Monitoring

What this Trial Is About

Researchers are evaluating the importance of the burden of new-onset atrial fibrillation NOAF in patients who develop this condition during acute myocardial infarction AMI hospitalization. This study aims to confirm earlier findings that a higher NOAF burden leads to worse outcomes and to understand factors that contribute to increasing NOAF burden after a heart attack. The study also seeks to create a prediction model to help assess risk and to explore how NOAF burden can guide blood-thinning treatment decisions in these patients. Patients admitted for AMI who develop NOAF during hospitalization will be included. Participants will have continuous electronic monitoring CEM for at least 5 days to measure NOAF burden, calculated as the total duration of atrial fibrillation divided by the total monitoring time. Patients will be divided into low or high NOAF burden groups based on a previously established threshold of 10.87%. This multicenter registry involves data collection from multiple hospitals and includes demographic information, heart health factors, lab tests, and imaging results to fully characterize participants. After discharge, all patients who survive will be followed for at least 2 years to record cardiovascular outcomes such as death, heart failure hospitalizations, recurrent heart attacks, strokes, and major bleeding events. The primary outcome is all-cause death within one year. The study uses continuous heart rhythm monitoring during hospitalization and gathers detailed clinical information to understand the impact of NOAF burden and its role in guiding treatment. Participation involves data collection during hospital stay and long-term follow-up visits to assess health outcomes.

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction